MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.250 -0.100 (-2.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Arbutus Biopharma Stock Is Plunging Today ↗
 
Via Benzinga
News headline image
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Biopharma's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Recap: Arbutus Biopharma Q2 Earnings ↗
  Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma ↗
 
Via Benzinga
News headline image
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots ↗
 
Via Benzinga
News headline image
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Participate in Three Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Resignation of Board Member
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗
 
Via Benzinga
News headline image
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares! 
Via InvestorPlace
News headline image
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know ↗
Moderna Inc (NASDAQ: MRNA) has  
Via Benzinga
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
News headline image
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story